Staar Surgical Celebrates 2 Million Lens Milestone for Implantable Collamer Lens (ICL)
Staar Surgical announced that more than 2 million Visian Implantable Collamer lenses (ICLs) have been sold globally, including more than one and a half million of the company’s latest generation of implantable lenses–EVO Visian ICLs (EVO). New to the U.S. market, EVO is available in more than 75 countries around the world.
“As we celebrate the 2 million lens milestone for Visian ICL, we extend our sincere appreciation to our surgeon and clinical partners embracing our lens-based vision correction technologies and their patients who have chosen ICL to break free from the hassles of glasses and frequent replacement contact lenses,” Caren Mason, President and CEO of Staar Surgical, said in a company news release. “In April 2019 we announced achievement of the first 1 million ICL lenses sold, and today, just about 3 years later, we are celebrating 2 million total ICLs sold. This most recent milestone follows the initial successful stages of commercialization of our EVO lenses in the US. Globally, our commitment to leading a lens-based future for refractive vision correction and achieving high levels of growth, led by EVO, will be propelled by our lenses’ clinical validation, a myriad of premium benefits associated with our lenses, and the many happy ICL patients enjoying improved quality of life who state they would have the procedure again."
The EVO Visian ICL is a family of phakic intraocular lenses (phakic means the natural crystalline lens is not removed) designed to correct for a wide range of vision correction needs including myopia (nearsightedness) and astigmatism. Myopia is predicted to impact 50% of the world’s population by the year 2050.2
References
1 99.4% of EVO patients would have the EVO ICL procedure again. Packer, The Implantable Collamer Lens with a central port: review of the literature, Clinical Ophthalmology, 2018.
2 Ophthalmology 2016;123:1036-1042 © 2016 by the American Academy of Ophthalmology.